全文获取类型
收费全文 | 73340篇 |
免费 | 5603篇 |
国内免费 | 1114篇 |
专业分类
耳鼻咽喉 | 296篇 |
儿科学 | 3422篇 |
妇产科学 | 976篇 |
基础医学 | 6578篇 |
口腔科学 | 1006篇 |
临床医学 | 9761篇 |
内科学 | 13515篇 |
皮肤病学 | 725篇 |
神经病学 | 1015篇 |
特种医学 | 2659篇 |
外国民族医学 | 1篇 |
外科学 | 7783篇 |
综合类 | 11288篇 |
现状与发展 | 7篇 |
预防医学 | 11414篇 |
眼科学 | 299篇 |
药学 | 6001篇 |
63篇 | |
中国医学 | 1562篇 |
肿瘤学 | 1686篇 |
出版年
2024年 | 170篇 |
2023年 | 1198篇 |
2022年 | 2617篇 |
2021年 | 3210篇 |
2020年 | 3167篇 |
2019年 | 2493篇 |
2018年 | 2468篇 |
2017年 | 2419篇 |
2016年 | 2634篇 |
2015年 | 2820篇 |
2014年 | 5082篇 |
2013年 | 5405篇 |
2012年 | 4903篇 |
2011年 | 5040篇 |
2010年 | 3744篇 |
2009年 | 3533篇 |
2008年 | 3433篇 |
2007年 | 3543篇 |
2006年 | 3288篇 |
2005年 | 2859篇 |
2004年 | 2284篇 |
2003年 | 1914篇 |
2002年 | 1396篇 |
2001年 | 1345篇 |
2000年 | 1084篇 |
1999年 | 1019篇 |
1998年 | 818篇 |
1997年 | 755篇 |
1996年 | 606篇 |
1995年 | 640篇 |
1994年 | 581篇 |
1993年 | 467篇 |
1992年 | 423篇 |
1991年 | 383篇 |
1990年 | 305篇 |
1989年 | 302篇 |
1988年 | 248篇 |
1987年 | 210篇 |
1986年 | 156篇 |
1985年 | 212篇 |
1984年 | 152篇 |
1983年 | 87篇 |
1982年 | 140篇 |
1981年 | 104篇 |
1980年 | 76篇 |
1979年 | 80篇 |
1978年 | 55篇 |
1977年 | 56篇 |
1976年 | 51篇 |
1975年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
J. Alarcón-Rodríguez M. Fernández-Velilla A. Ureña-Vacas J.J. Martín-Pinacho J.A. Rigual-Bobillo A. Jaureguízar-Oriol L. Gorospe-Sarasúa 《Radiologia》2021,63(3):258-269
Most of the patients who overcome the SARS-CoV-2 infection do not present complications and do not require a specific follow-up, but a significant proportion (especially those with moderate / severe clinical forms of the disease) require clinicalradiological follow-up. Although there are hardly any references or clinical guidelines regarding the long-term follow-up of post-COVID-19 patients, radiological exams are being performed and monographic surveillance consultations are being set up in most of the hospitals to meet their needs. The purpose of this work is to share our experience in the management of the post-COVID-19 patient in two institutions thathave had a high incidence of COVID-19 and to propose general follow-uprecommendations from a clinical and radiological perspective. 相似文献
52.
Samira Marín-Romero Teresa Elías-Hernández María Isabel Asensio-Cruz Rocío Ortega-Rivera Raquel Morillo-Guerrero Javier Toral Emilio Montero Verónica Sánchez Elena Arellano José María Sánchez-Díaz Macarena Real-Domínguez Remedios Otero-Candelera Luis Jara-Palomares 《Archivos de bronconeumología》2019,55(12):619-626
IntroductionScales for predicting venous thromboembolism (VTE) recurrence are useful for deciding the duration of the anticoagulant treatment. Although there are several scales, the most appropriate for our setting has not been identified. For this reason, we aimed to validate the DASH prediction score and the Vienna nomogram at 12 months.MethodsThis was a retrospective study of unselected consecutive VTE patients seen between 2006 and 2014. We compared the ability of the DASH score and the Vienna nomogram to predict recurrences of VTE. The validation was performed by stratifying patients as low-risk or high-risk, according to each scale (discrimination) and comparing the observed recurrence with the expected rate (calibration).ResultsOf 353 patients evaluated, 195 were analyzed, with an average age of 53.5 ± 19 years. There were 21 recurrences in 1 year (10.8%, 95% CI: 6.8%-16%). According to the DASH score, 42% were classified as low risk, and the rate of VTE recurrence in this group was 4.9% (95% CI: 1.3%-12%) vs. the high-risk group that was 15% (95% CI: 9%-23%) (p <.05). According to the Vienna nomogram, 30% were classified as low risk, and the rate of VTE recurrence in the low risk group vs. the high risk group was 4.2% (95% CI:0.5%-14%) vs. 16.2% (95% CI: 9.9%-24.4%) (p <.05).ConclusionsOur study validates the DASH score and the Vienna nomogram in our population. The DASH prediction score may be the most advisable, both because of its simplicity and its ability to identify more low-risk patients than the Vienna nomogram (42% vs. 30%). 相似文献
53.
54.
55.
56.
57.
58.
59.
AbstractBackground: This study aims to compare the effectiveness of inhaled prostacyclin or its analoguesversus nitric oxide (NO) in treating pulmonary hypertension (PH) after cardiac or pulmonary surgery remains unclear.Methods: PubMed, Cochrane, and Embase databases were searched for literature published prior to December 2019 using the following keywords: inhaled, nitric oxide, prostacyclin, iloprost, treprostinil, epoprostenol, Tyvaso, flolan, and pulmonary hypertension. Randomized controlled trials and multiple-armed prospective studies that evaluated inhaled NO versus prostacyclin (or analogues) in patients for perioperative and/or postoperative PH after either cardiac or pulmonary surgery were included. Retrospective studies, reviews, letters, comments, editorials, and case reports were excluded.Results: Seven studies with a total of 195 patients were included. No difference in the improvement of mean pulmonary arterial pressure (pooled difference in mean change= ?0.10, 95% CI: ?3.98 to 3.78, p?=?.959) or pulmonary vascular resistance (pooled standardized difference in mean change= ?0.27, 95% CI: ?0.60 to 0.05, p?=?.099) were found between the two treatments. Similarly, no difference was found in other outcomes between the two treatments or subgroup analysis.Conclusions: Inhaled prostacyclin (or analogues) was comparable to inhaled NO in treating PH after cardiac or pulmonary surgery.
- Key messages
This study compared the efficacy of inhaled prostacyclin or its analogues versus inhaled NO to treat PH after surgery. The two types of agent exhibited similar efficacy in managing MPAP, PVR, heart rate, and cardiac output was observed.
Inhaled prostacyclin may serve as an alternative treatment option for PH after cardiac or pulmonary surgery.
60.
Brenda Laky Isabella Alram Julia K. Frank Leo Pauzenberger Werner Anderl Karl-Heinz Wagner Philipp R. Heuberer 《Journal of orthopaedic research》2020,38(9):2074-2082
Increasing numbers of arthroplasties are also accompanied by postoperative infections. The main purpose was to evaluate preoperative serum bilirubin levels between patients with and without infections after shoulder and knee arthroplasties. For this retrospective case-control single-center study, a total of 108 patients were extracted from a prospectively collected database. Eighteen patients with infections after shoulder (n = 8) and knee (n = 10) arthroplasty were matched by age, gender, and implant type in a 1:5-scenario to 90 patients (40 shoulders and 50 knees) without postoperative infection. Demographic data, preoperative blood parameters, and postoperative infection-related outcomes were evaluated. Total bilirubin was the only preoperative parameter significantly different between the infection (8.21 ± 3.25 μmol/L or 0.48 ± 0.19 mg/dL) and noninfection (10.78 ± 4.62 μmol/L or 0.63 ± 0.27 mg/dL; P = .014) group, while C-reactive protein and other liver parameters were similar between the groups. Significantly more controls (92.1%) had preoperative bilirubin levels above 8.72 μmol/L or 0.51 mg/dL than cases (7.9%; P = .007). The 5-year infection survival-rate was 65.6% for patients with preoperative bilirubin levels < 8.72 μmol/L or < 0.51 mg/dL and 91.2% with ≥ 8.72 μmol/L or ≥ 0.51 mg/dL. Mildly decreased preoperative bilirubin levels with a cutoff at 8.72 μmol/L or 0.51 mg/dL were significantly associated to patients with infections after shoulder and knee arthroplasty. There were no differences in other blood parameters or comorbidities between patients with infections and their matched-controls. 相似文献